Lovaza and Speech disorder - a phase IV clinical study of FDA data

Summary:

Speech disorder is reported as a side effect among people who take Lovaza (omega-3-acid ethyl esters), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Aspirin, and have Pain.

The phase IV clinical study analyzes which people have Speech disorder when taking Lovaza. It is created by eHealthMe based on reports of 16,646 people who have side effects when taking Lovaza from the FDA, and is updated regularly.

What is Lovaza?

Lovaza has active ingredients of omega-3-acid ethyl esters. It is often used in high blood cholesterol. eHealthMe is studying from 17,340 Lovaza users. Check the latest studies of Lovaza.

What is Speech disorder?

Speech disorder is found to be associated with 1,808 drugs and 2,279 conditions by eHealthMe. Check the latest studies of Speech disorder.

On Jul, 21, 2026

16,646 people reported to have side effects when taking Lovaza.
Among them, 75 people (0.45%) have Speech disorder.

Among these 75 people:

How long have people been on Lovaza when they have Speech disorder? *

What is the gender of people who have Speech disorder when taking Lovaza? *

female: 65.33 %
male: 34.67 %

What is the age of people who have Speech disorder when taking Lovaza? *

What are other drugs people take besides Lovaza? *

What are other side effects people have besides Speech disorder? *

Dizziness: 24 people, 32.00%
Memory Loss: 24 people, 32.00%
Weakness: 19 people, 25.33%
Fatigue (feeling of tiredness): 18 people, 24.00%
Depression: 15 people, 20.00%
Gait Disturbance: 15 people, 20.00%
Cough: 15 people, 20.00%
Hyperhidrosis (abnormally increased sweating): 13 people, 17.33%
Confusional State: 12 people, 16.00%
Joint Pain: 12 people, 16.00%

What are the existing conditions these people have? *

Pain: 12 people, 16.00%
High Blood Pressure: 11 people, 14.67%
Osteoporosis (bones weak and more likely to break): 7 people, 9.33%
Cardiac Disorder: 6 people, 8.00%
Migraine (headache): 6 people, 8.00%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 6 people, 8.00%
Weakness: 5 people, 6.67%
Asthma: 5 people, 6.67%
Constipation: 5 people, 6.67%
Neuralgia (pain in one or more nerves): 5 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Lovaza and have Speech disorder?

- Check whether Speech disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lovaza:

Lovaza (17,340 reports)

Speech disorder treatments and more:

Speech disorder (62,574 reports)

Browse all side effects of Lovaza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Speech disorder:

Speech disorder (1,808 drugs)

Browse all the conditions that are associated with Speech disorder:

Speech disorder (2,279 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on omega-3-acid ethyl esters (the active ingredients of Lovaza) and Lovaza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.